Bet v 1 is the major allergen in birch pollen to which up to 95% of patients sensitized to birch respond. As a member of the pathogenesis-related PR 10 family, its natural function is implicated in plant defense, with a member of the PR10 family being reported to be upregulated under iron deficiency. As such, we assessed the function of Bet v 1 to sequester iron and its immunomodulatory properties on human immune cells. Binding of Bet v 1 to iron quercetin complexes FeQ2 was determined in docking calculations and by spectroscopy. Serum IgE-binding to Bet v 1 with (holoBet v1) and without ligands (apoBet v 1) were assessed by ELISA, blocking experiments and Western Blot. Crosslinking-capacity of apo/holoBet v 1 were assessed on human mast cells and Arylhydrocarbon receptor (AhR) activation with the human reporter cellline AZ-AHR. Human PBMCs were stimulated and assessed for labile iron and phenotypic changes by flow cytometry. Bet v 1 bound to FeQ2 strongly with calculated Kd values of 1 nm surpassing affinities to quercetin alone nearly by a factor of 1000. Binding to FeQ2 masked IgE epitopes and decreased IgE binding up to 80% and impaired degranulation of sensitized human mast cells. Bet v 1 facilitated the shuttling of quercetin, which activated the anti-inflammatory AhR pathway and increased the labile iron pool of human monocytic cells. The increase of labile iron was associated with an anti-inflammatory phenotype in CD14+monocytes and downregulation of HLADR. To summarize, we reveal for the first time that FeQ2 binding reduces the allergenicity of Bet v 1 due to ligand masking, but also actively contributes anti-inflammatory stimuli to human monocytes, thereby fostering tolerance. Nourishing immune cells with complex iron may thus represent a promising antigen-independent immunotherapeutic approach to improve efficacy in allergen immunotherapy.

Center for Plant Biotechnology and Genomics Biotechnology Department ETSIAAB CBGP Universidad Politécnica de Madrid 28040 Madrid Spain

Center of Pathophysiology Infectiology and Immunology Institute of Pathophysiology and Allergy Research Medical University of Vienna 1090 Vienna Austria

Comparative Medicine The Interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna Medical University Vienna and University of Vienna 1210 Vienna Austria

Department of Biosciences University of Salzburg 5020 Salzburg Austria

Department of Cell Biology and Genetics Faculty of Science Palacky University 78371 Olomouc Czech Republic

Division of Pharmacology Utrecht Institute for Pharmaceutical Sciences Faculty of Science Utrecht University 3584 CG Utrecht The Netherlands

000      

00000naa a2200000 a 4500

001      

bmc23003318

003      

CZ-PrNML

005      

20230421100122.0

007      

ta

008      

230413s2022 sz f 000 0|eng||

009      

AR

024    7_

$a 10.3390/antiox12010042 $2 doi

035    __

$a (PubMed)36670905

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a sz

100    1_

$a Regner, Andreas $u Comparative Medicine, The Interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna, Medical University Vienna and University of Vienna, 1210 Vienna, Austria

245    10

$a Binding to Iron Quercetin Complexes Increases the Antioxidant Capacity of the Major Birch Pollen Allergen Bet v 1 and Reduces Its Allergenicity / $c A. Regner, N. Szepannek, M. Wiederstein, A. Fakhimahmadi, LF. Paciosis, BR. Blokhuis, FA. Redegeld, G. Hofstetter, Z. Dvorak, E. Jensen-Jarolim, K. Hufnagl, F. Roth-Walter

520    9_

$a Bet v 1 is the major allergen in birch pollen to which up to 95% of patients sensitized to birch respond. As a member of the pathogenesis-related PR 10 family, its natural function is implicated in plant defense, with a member of the PR10 family being reported to be upregulated under iron deficiency. As such, we assessed the function of Bet v 1 to sequester iron and its immunomodulatory properties on human immune cells. Binding of Bet v 1 to iron quercetin complexes FeQ2 was determined in docking calculations and by spectroscopy. Serum IgE-binding to Bet v 1 with (holoBet v1) and without ligands (apoBet v 1) were assessed by ELISA, blocking experiments and Western Blot. Crosslinking-capacity of apo/holoBet v 1 were assessed on human mast cells and Arylhydrocarbon receptor (AhR) activation with the human reporter cellline AZ-AHR. Human PBMCs were stimulated and assessed for labile iron and phenotypic changes by flow cytometry. Bet v 1 bound to FeQ2 strongly with calculated Kd values of 1 nm surpassing affinities to quercetin alone nearly by a factor of 1000. Binding to FeQ2 masked IgE epitopes and decreased IgE binding up to 80% and impaired degranulation of sensitized human mast cells. Bet v 1 facilitated the shuttling of quercetin, which activated the anti-inflammatory AhR pathway and increased the labile iron pool of human monocytic cells. The increase of labile iron was associated with an anti-inflammatory phenotype in CD14+monocytes and downregulation of HLADR. To summarize, we reveal for the first time that FeQ2 binding reduces the allergenicity of Bet v 1 due to ligand masking, but also actively contributes anti-inflammatory stimuli to human monocytes, thereby fostering tolerance. Nourishing immune cells with complex iron may thus represent a promising antigen-independent immunotherapeutic approach to improve efficacy in allergen immunotherapy.

590    __

$a NEINDEXOVÁNO

655    _2

$a časopisecké články $7 D016428

700    1_

$a Szepannek, Nathalie $u Comparative Medicine, The Interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna, Medical University Vienna and University of Vienna, 1210 Vienna, Austria

700    1_

$a Wiederstein, Markus $u Department of Biosciences, University of Salzburg, 5020 Salzburg, Austria $1 https://orcid.org/0000000247504746

700    1_

$a Fakhimahmadi, Aila $u Comparative Medicine, The Interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna, Medical University Vienna and University of Vienna, 1210 Vienna, Austria $u Center of Pathophysiology, Infectiology and Immunology, Institute of Pathophysiology and Allergy Research, Medical University of Vienna, 1090 Vienna, Austria

700    1_

$a Paciosis, Luis F $u Center for Plant Biotechnology and Genomics, Biotechnology Department, ETSIAAB, CBGP (UPM-INIA), Universidad Politécnica de Madrid, 28040 Madrid, Spain $1 https://orcid.org/0000000205854289

700    1_

$a Blokhuis, Bart R $u Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, 3584 CG Utrecht, The Netherlands $1 https://orcid.org/0000000293666404

700    1_

$a Redegeld, Frank A $u Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, 3584 CG Utrecht, The Netherlands $1 https://orcid.org/0000000188307960

700    1_

$a Hofstetter, Gerlinde $u Comparative Medicine, The Interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna, Medical University Vienna and University of Vienna, 1210 Vienna, Austria

700    1_

$a Dvorak, Zdenek $u Department of Cell Biology and Genetics, Faculty of Science, Palacky University, 78371 Olomouc, Czech Republic $1 https://orcid.org/0000000239383585 $7 xx0118950

700    1_

$a Jensen-Jarolim, Erika $u Comparative Medicine, The Interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna, Medical University Vienna and University of Vienna, 1210 Vienna, Austria $u Center of Pathophysiology, Infectiology and Immunology, Institute of Pathophysiology and Allergy Research, Medical University of Vienna, 1090 Vienna, Austria $1 https://orcid.org/0000000340195765 $7 ntk20221155367

700    1_

$a Hufnagl, Karin $u Comparative Medicine, The Interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna, Medical University Vienna and University of Vienna, 1210 Vienna, Austria $u Center of Pathophysiology, Infectiology and Immunology, Institute of Pathophysiology and Allergy Research, Medical University of Vienna, 1090 Vienna, Austria

700    1_

$a Roth-Walter, Franziska $u Comparative Medicine, The Interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna, Medical University Vienna and University of Vienna, 1210 Vienna, Austria $u Center of Pathophysiology, Infectiology and Immunology, Institute of Pathophysiology and Allergy Research, Medical University of Vienna, 1090 Vienna, Austria $1 https://orcid.org/0000000150059228

773    0_

$w MED00200130 $t Antioxidants (Basel, Switzerland) $x 2076-3921 $g Roč. 12, č. 1 (2022)

856    41

$u https://pubmed.ncbi.nlm.nih.gov/36670905 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20230413 $b ABA008

991    __

$a 20230421100115 $b ABA008

999    __

$a ok $b bmc $g 1922864 $s 1189525

BAS    __

$a 3

BAS    __

$a PreBMC-PubMed-not-MEDLINE

BMC    __

$a 2022 $b 12 $c 1 $e 20221226 $i 2076-3921 $m Antioxidants $n Antioxidants (Basel) $x MED00200130

LZP    __

$a Pubmed-20230413